EXACT Sciences

FDA approves Freenome colorectal cancer blood test

Abbott will pay Freenome $100 million as part of a 2025 deal covering the test’s U.S. commercialization in adults 45 and older who are at average risk for colorectal cancer.

Ben Adams Jul 27, 2026 10:29am

Abbott lowers EPS guidance on Exact Sciences buy as shares slide

Apr 17, 2026 9:01am

Abbott inks $23B deal for Exact Sciences in cancer testing buy

Nov 20, 2025 10:30am

Exact Sciences rolls out Cancerguard multi-cancer blood test

Sep 11, 2025 1:00pm

Exact Sciences plans 'transformative year' with new cancer tests

May 1, 2025 4:05pm

Exact Sciences kicks off launch of next-gen Cologuard Plus test

Mar 31, 2025 6:00am